Amedisys (AMED) Competitors

Chemed (NYSE:CHE) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations.

Is CHE or AMED more profitable?

Chemed has a net margin of 12.69% compared to Amedisys' net margin of 3.57%. Chemed's return on equity of 27.86% beat Amedisys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	12.69%	27.86%	19.12%
Amedisys	3.57%	12.20%	6.74%

Does the media prefer CHE or AMED?

In the previous week, Chemed had 6 more articles in the media than Amedisys. MarketBeat recorded 8 mentions for Chemed and 2 mentions for Amedisys. Chemed's average media sentiment score of 1.18 beat Amedisys' score of 1.00 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Amedisys	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Do analysts recommend CHE or AMED?

Chemed presently has a consensus target price of $641.50, suggesting a potential upside of 22.62%. Amedisys has a consensus target price of $100.67, suggesting a potential upside of 19.17%. Given Chemed's stronger consensus rating and higher probable upside, equities research analysts plainly believe Chemed is more favorable than Amedisys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amedisys	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Does the MarketBeat Community favor CHE or AMED?

Amedisys received 163 more outperform votes than Chemed when rated by MarketBeat users. However, 63.48% of users gave Chemed an outperform vote while only 58.72% of users gave Amedisys an outperform vote.

Company	Underperform	Outperform
Chemed	Outperform Votes 332 63.48%	Underperform Votes 191 36.52%
Amedisys	Outperform Votes 495 58.72%	Underperform Votes 348 41.28%

Do institutionals and insiders believe in CHE or AMED?

95.8% of Chemed shares are owned by institutional investors. Comparatively, 94.4% of Amedisys shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 2.1% of Amedisys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has higher earnings and valuation, CHE or AMED?

Chemed has higher revenue and earnings than Amedisys. Chemed is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.38B	3.31	$272.51M	$19.79	26.44
Amedisys	$2.32B	1.19	-$9.75M	$2.52	33.52

Which has more volatility & risk, CHE or AMED?

Chemed has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Summary

Chemed beats Amedisys on 15 of the 18 factors compared between the two stocks.